Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Novo Nordisk has asked the FDA to stop compounding pharmacies making cheaper versions of its semaglutide-based therapies for obesity and diabetes, saying the drug is too complex to be made safely ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

To intensify its efforts towards a sustainable future, the People's Action Party (PAP) has launched a new Climate Action Group (CAG). In a speech on Jan. 21, 2025, PAP assistant secretary general ...

After hours: 7:59:57 pm GMT-5 ...